Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva
This article was originally published in Pharmaceutical Approvals Monthly
Novartis AG, looking to position its once-daily Onbrez Breezhaler (indacaterol) to steal market share from the only once-daily bronchodilator approved for chronic obstructive pulmonary disease, Boehringer Ingelheim GMBH/Pfizer Inc.’s Spiriva (tiotropium), released Phase III data from a head-to-head study comparing the two products.
You may also be interested in...
Generics are looming for top-selling chronic obstructive pulmonary disease therapies, but Big Pharma continues to see tremendous growth opportunities in the space
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.